GW Pharmaceuticals plcGWPH is a biopharmaceutical company that focuses on developing and commercializing candidates based on its proprietary cannabinoid platform in a broad range of disease areas. The company's key growth driver, Sativex, is approved outside the U.S. for the treatment of spasticity associated with multiple sclerosis. GW Pharma is also developing various other cannabinoid-based treatments for indications like glioma, ulcerative colitis, schizophrenia and type II diabetes.
In this scenario, investor focus remains on pipeline updates since a number of pipeline related activities are lined up in 2016 apart from the usual top-and bottom-line numbers.
GW Pharma's pipeline includes Epidiolex, currently in phase III development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. Data from the first and the second phase III Dravet syndrome study is expected in Mar 2016 and in the second half of 2016, respectively. Meanwhile, data from two phase III Lennox-Gastaut syndrome studies are expected in the second quarter of 2016.
The company expects to file for a New Drug Application (NDA) for Epidiolex in the fourth quarter of 2016.
Currently, GW Pharma has a Zacks Rank #2 (Buy), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: GW Pharma reported narrower-than-expected first quarter loss. Our consensus called for a loss of $1.84 cents per share and the company reported a loss of $1.2 per share.
Revenues: Revenues exceeded expectations. GW Pharma posted revenues of $5.4 million, compared to our consensus estimate of $4 million.
Key Stats: Sativex continues to drive revenues at GW Pharma. Currently, the company is developing Sativex in a phase II study for spasticity due to cerebral palsy with data expected in the second half of 2016. Data from the pivotal studies on the epilepsy candidate, Epidiolex (Dravet and Lennox-Gastaut syndrome) are expected in the coming quarters. The company plans to file an NDA for Epidiolex in the fourth quarter of 2016.
Check back later for our full write up on earnings report later!